Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
Author:
Funder
Wilhelm Sander-Stiftung
Publisher
Frontiers Media SA
Subject
Immunology,Immunology and Allergy
Reference48 articles.
1. NAD(+)-Metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model;Horenstein;Cells,2015
2. The pharmacology of CD38/NADase: an emerging target in cancer and diseases of aging;Chini;Trends Pharmacol Sci.,2018
3. Immunotherapy: A new approach to treating multiple myeloma with daratumumab and elotuzumab;Afifi;Ann Pharmacother.,2016
4. New investigational drugs with single-agent activity in multiple myeloma;Rajan;Blood Cancer J.,2016
5. CD38 antibodies in multiple myeloma: back to the future;van;Blood,2017
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors;Frontiers in Immunology;2022-11-02
2. Evolving therapeutic proteins to precisely kill cancer cells;Journal of Controlled Release;2022-11
3. CD38-specific nanobodies allow in vivo imaging of multiple myeloma under daratumumab therapy;Frontiers in Immunology;2022-10-27
4. Immunogenicity of Monoclonal Antibodies and the Potential Use of HLA Haplotypes to Predict Vulnerable Patients;Frontiers in Immunology;2022-06-17
5. Half-Life Extended Nanobody-Based CD38-Specific Bispecific Killercell Engagers Induce Killing of Multiple Myeloma Cells;Frontiers in Immunology;2022-05-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3